Evidence map›Paper›PMID 34625989›Full record

ArticleScandinavian journal of immunology2022

Correlation of myeloid-derived suppressor cells with C-reactive protein, ferritin and lactate dehydrogenase levels in patients with severe COVID-19.

Ayca Emsen, Sua Sumer, Baykal Tulek, Hilal Cizmecioglu, Husamettin Vatansev, Mevlut Hakan Goktepe, Fikret Kanat, Yavuz Koksal, Ugur Arslan, Hasibe Artac

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in Scandinavian journal of immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Immune cell disorder in viral pneumonia.Journal of translational medicine · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Myeloid-derived suppressor cells in COVID-19: A review.Clinical immunology (Orlando, Fla.) · 2022
    Review
  9. Article
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Ayca EmsenDepartment of Pediatric Immunology and Allergy, Faculty of Medicine, Selcuk University, Konya, Turkey.ORCID https://orcid.org/0000-0003-3028-3112
Sua SumerDepartment of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Baykal TulekDepartment of Respiratory Diseases, Faculty of Medicine, Selcuk University, Konya, Turkey.
Hilal CizmeciogluDepartment of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Husamettin VatansevDepartment of Medical Biochemistry, Faculty of Medicine, Selcuk University, Konya, Turkey.
Mevlut Hakan GoktepeDepartment of Internal Medicine, Faculty of Medicine, Necmettin Erbakan University, Konya, Turkey.
Fikret KanatDepartment of Respiratory Diseases, Faculty of Medicine, Selcuk University, Konya, Turkey.
Yavuz KoksalDepartment of Pediatric Oncology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Ugur ArslanDepartment of Medical Microbiology, Faculty of Medicine, Selcuk University, Konya, Turkey.
Hasibe ArtacDepartment of Pediatric Immunology and Allergy, Faculty of Medicine, Selcuk University, Konya, Turkey.
Selçuk University · TRNecmettin Erbakan University · TR

Funding

Selcuk University 18611484
6 · The paper itself

Abstract

The novel coronavirus disease 2019 (COVID-19) remains a global health emergency, and understanding the interactions between the virus and host immune responses is crucial to preventing its lethal effects. The expansion of myeloid-derived suppressor cells (MDSCs) in COVID-19, thereby suppressing immune responses, has been described as responsible for the severity of the disease, but the correlation between MDSC subsets and COVID-19 severity remains elusive. Therefore, we classified patients according to clinical and laboratory findings-aiming to investigate the relationship between MDSC subsets and laboratory findings such as high C-reactive protein, ferritin and lactate dehydrogenase levels, which indicate the severity of the disease. Forty-one patients with COVID-19 (26 mild and 15 severe; mean age of 49.7 ± 15 years) and 26 healthy controls were included in this study. MDSCs were grouped into two major subsets-polymorphonuclear MDSCs (PMN-MDSCs) and monocytic MDSCs-by flow cytometric immunophenotyping, and PMN-MDSCs were defined as mature and immature, according to CD16 expressions, for the first time in COVID-19. Total MDSCs, PMN-MDSCs, mature PMN-MDSCs and monocytic MDSCs were significantly higher in patients with COVID-19 compared with the healthy controls (P < .05). Only PMN-MDSCs and their immature PMN-MDSC subsets were higher in the severe subgroup than in the mild subgroup. In addition, a significant correlation was found between C-reactive protein, ferritin and lactate dehydrogenase levels and MDSCs in patients with COVID-19. These findings suggest that MDSCs play a role in the pathogenesis of COVID-19, while PMN-MDSCs, especially immature PMN-MDSCs, are associated with the severity of the disease.

Indexed as

Acute-Phase ProteinsAdultAgedCase-Control StudiesCOVID-19C-Reactive ProteinDisease ProgressionFemaleFerritinsHumansL-Lactate DehydrogenaseMaleMiddle AgedMyeloid-Derived Suppressor CellsProspective StudiesSARS-CoV-2Acute-Phase ProteinsC-Reactive ProteinFerritinsL-Lactate DehydrogenaseCOVID-19MDSC subsets and acute-phase reactants

Identifiers

PMID34625989
PMCPMC8646635
OpenAlexW3204614687

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.